Early and easy-to-retrieve predictive biomarkers of resistance to immunotherapy in microsatellite instability (MSI)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Vaghi, C. [1 ]
Ros Montana, F. J. [2 ]
Mambrilla, M. [3 ]
Navarro Garces, V. [3 ]
Comas, R. [3 ]
Salva Ballabrera, F. [4 ]
Baraibar Argota, I. [5 ]
Saoudi Gonzalez, N. [5 ]
Rodriguez Castells, M. [2 ]
Garcia Rodriguez, A. [5 ]
Alcaraz, A. [6 ]
Tabernero, J. [2 ]
Elez Fernandez, M. E. [2 ]
机构：
[1] ASST Grande Osped Metropolitano Niguarda, Oncol Dept, Milan, Italy
[2] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
[3] Vall dHebron Inst Oncol VHIO, Oncol Data Sci Grp, Barcelona, Spain
[4] Vall dHebron Univ Hosp, Gastrointestinal Unit, Med Oncol, Barcelona, Spain
[5] Vall dHebron Univ Hosp, Dept Oncol, Barcelona, Spain
[6] Vall dHebron Univ Hosp, Colon Canc Dept, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.132
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
121P
引用
收藏
页码：S56 / S57
页数：2
相关论文
共 50 条
  • [21] Targeted treatment (TT) after immune checkpoint inhibitors (ICIs) in BRAF V600E mutated (BRAFm) and deficient mismatch repair or microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC)
    Ambrosini, M.
    Tougeron, D.
    Modest, P.
    Guimbaud, R.
    Kopetz, S.
    Decraecker, M.
    Sclafani, F.
    Coutzac, C.
    Lievre, A.
    Alouani, E. L.
    Marmorino, F.
    Pernot, S.
    Sinicrope, A.
    Elez Fernandez, E.
    Germani, M. M.
    Pietrantonio, F.
    Lonardi, S.
    Parent, P.
    Gallois, C.
    Taieb, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S32 - S32
  • [22] Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study.
    Kopetz, Scott
    Lonardi, Sara
    McDermott, Raymond S.
    Aglietta, Massimo
    Hendlisz, Alain
    Morse, Michael
    Leach, Joseph W.
    Neyns, Bart
    Chan, Emily
    Chen, Franklin
    Wong, Ka Yeung Mark
    Lee, James J.
    Garcia-Alfonso, Pilar
    Hill, Andrew G.
    Lenz, Heinz-Josef
    Desai, Jayesh
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers
    Stemmer, Amos
    Margalit, Ofer
    Serpas, Victoria
    Strauss, Gal
    Thomas, Jane
    Shah, Preksha
    Tau, Noam
    Levanon, Keren
    Shacham-Shmueli, Einat
    Kopetz, Scott
    Overman, Michael
    Boursi, Ben
    EUROPEAN JOURNAL OF CANCER, 2024, 198
  • [24] A phase 3 study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
    Andre, T.
    Van Cutsem, E.
    Elez, E.
    Bennouna, J.
    de la Fouchardiere, C.
    Yoshino, T.
    Jensen, L.
    Mendez, G.
    Li, J.
    Goekkurt, E.
    Abdullaev, S.
    Chen, T.
    Lei, M.
    Lonardi, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S250 - S250
  • [25] Nivolumab plus ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.
    Andre, Thierry
    Lonardi, Sara
    Wong, Mark
    Lenz, Heinz-Josef
    Gelsomino, Fabio
    Aglietta, Massimo
    Morse, Michael
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hill, Andrew G.
    Sawyer, Michael B.
    Hendlisz, Alain
    Neyns, Bart
    Svrcek, Magali
    Moss, Rebecca Anne
    Ledeine, Jean-Marie
    Cao, Z. Alexander
    Kamble, Shital
    Kopetz, Scott
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [26] RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab combination in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Results of the GERCOR NIPICOL phase II study
    Cohen, Romain
    Bennouna, Jaafar
    Henriques, Julie
    Tournigand, Christophe
    De La Fouchardiere, Christelle
    Tougeron, David
    Borg, Christophe
    Mazard, Thibault
    Chibaudel, Benoist
    Garcia-Larnicol, Marie-Line
    Svrcek, Magali
    Vernerey, Dewi
    Menu, Yves
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [27] Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)
    Lenz, H-J. J.
    Van Cutsem, E.
    Limon, M. L.
    Wong, K. Y.
    Hendlisz, A.
    Aglietta, M.
    Garcia-Alfonso, P.
    Neyns, B.
    Luppi, G.
    Cardin, D.
    Dragovich, T.
    Shah, U.
    Atasoy, A.
    Postema, R.
    Boyd, Z.
    Ledeine, J-M.
    Overman, M.
    Lonardi, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 714 - 714
  • [28] Mismatch repair/microsatellite instability (MMR/MSI) testing practices among United States physicians treating patients (pts) with advanced/metastatic colorectal cancer (mCRC).
    Eriksson, Jennifer
    Amonkar, Mayur
    Thomson, Gemma
    Lambert, Jeremy
    Malmenas, Mia
    Chase, Monica
    Sun, Lucy
    Kollmar, Linda Grossman
    Vichnin, Michelle
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [29] Potential drug cost impact of nivolumab (N) in Canada in patients with DNA mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC)
    Virik, Kiran
    Biagi, James Joseph
    Wilson, Robert B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [30] Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors: A Structured Literature Review
    Lorenzi, Maria
    Amonkar, Mayur
    Zhang, Jacky
    Mehta, Shivani
    Liaw, Kai-Li
    JOURNAL OF ONCOLOGY, 2020, 2020
12345